Monocyte/Macrophages are implicated in initiation of angiogenesis, tissue/organ perfusion and atherosclerosis biology. We recently showed that chemokine receptor CX 3 CR1 is an essential regulator of monocyte/macrophage derived smooth muscle cell differentiation in the vessel wall after injury. Here we hypothesised the contribution of CX 3 CR1-CX 3 CL1 interaction to in vivo neovascularization and studied the functional consequences of genetic and pharmacologic targeting of CX 3 CR1 in formation, maturation and maintenance of microvascular integrity. Cells functionally deficient in CX 3 CR1 lacked matrix tunnelling and tubulation capacity in a 3D Matrigel assay. These morphogenic and cytokinetic responses were driven by CX 3 CL1-CX 3 CR1 interaction and totally abrogated by a Rho antagonist. To evaluate the role of CX 3 CR1 system in vivo, Matrigel plugs were implanted in competent CX 3 CR1
Introduction
The monocyte-macrophage system (MPS) exhibits numerous functions with respect to vascular remodeling which include classical phagocytosis, regulation of antigen presentation and atherosclerotic plaque formation [1, 2, 3, 4] . MPS has also been implicated in paracrine-mediated pro-angiogenic and vascular structure changes orchestrated in response to cues as diverse as atherosclerotic plaque progression, tissue injury and ischemia, inflammation and tumour infiltration [5, 6, 7, 8, 9, 10, 11] . For instance, macrophages have been reported to tunnel through stromal architecture of numerous tissues including the heart and the retina connecting putative microvascular networks [4, 12, 13, 14, 15] . However, the mechanism and molecular regulators underlying this process are largely unknown and it remains unclear whether this is a generalized feature of MPS infiltration of tissues or if it represents a more specialized function of cellular components of MPS that might be a target for pharmacologic modification.
We have previously identified a CX 3 CR1 monocyte subpopulation capable of phagocytic functions typical of classical MPS as well as mural vascular smooth muscle cell-like functions that occur subsequent to CX 3 CL1-CX 3 CR1 interaction in the injured vessel wall [16, 17] . Interference with CX 3 CL1-CX 3 CR1 interaction was also observed to decrease neointima formation and atherosclerosis in murine animal models [17, 18, 19] , thus implicating the CX 3 CL1-CX 3 CR1 axis in atherosclerotic plaque development. Moreover polymorphisms in CX 3 CR1 receptors have been associated with variability in prevalence of human atherosclerosis and coronary artery disease [19] . Given that monocyte/macrophages are proposed to participate in angiogenesis [1, 4, 20, 21, 22] we hypothesized that CX 3 CL1-CX 3 CR1 signaling may also be implicated in mural cell fate determination during plaque microvessel formation both in terms of cell recruitment to the perivascular space but also in cytoskeletal re-organization of recruited mural cells that integrate into nascent and maturing microvessels. In the current study we selected the chemokine receptor CX 3 CR1 as a transgenic marker allowing baseline and loss of function status to be examined in mice that had green fluorescence protein knocked in at one or both CX 3 CR1 alleles [17, 23] . This facilitated simultaneous in vivo tracking of a major monocyte/macrophage subset into evolving neovascularization networks in solid matrix and in medium sized vessel wall microvasculature. These transgenic models also facilitated interrogation of loss of CX 3 CR1 function effects on CX 3 CR1 cell recruitment to the perivascular space, mural cell integration into evolving microvasculature, microvessel maturation and extracellular matrix production and microvessel haemorrhage and permeability. In vitro studies evaluated the signaling pathway downstream of CX 3 CR1 activation and its effects on cytoskeletal re-organization and solid matrix tunneling of CX 3 CR1 positive cells.
We show here for the first time that interaction between CX 3 CL1 and CX 3 CR1 initiates signaling through a Rho dependent pathway that promotes cell tubulation and tunneling through extracellular matrix. Moreover, functional competence of CX 3 CR1 to interact with its cognate ligand CX 3 CL1 is essential for microvessel maturation and expansion, and monocyte/ macrophage-derived mural cell integration into evolving vasculature during neovascularization in vivo. Finally, CX 3 CR1 deficiency or therapeutic targeting with a peptide-antagonist reduces experimental plaque and Matrigel neovascularization but favours a leaky, haemorrhagic microvessel phenotype. 
Materials and Methods

Animals
CX 3 CR1 peptide antagonist (F1)
The CX 3 CR1 peptide antagonist (F1) was engineered from phage library of CX 3 CL1 mutants consisting of modified N terminus (QHHGVT sequence of the native CX 3 CL1 replaced with ILDNGVS). F1 peptide was purified from E. Coli inclusion bodies using standard procedures and its specificity to CX 3 CR1 receptor and pharmacodynamics has previously been described [24] . Based on the static adhesion assay and prior pharmacodynamics data [24] , 50 mg of F1 peptide was dissolved in 100 ml of saline and administered intraperitoneally every third day from the 2 nd to 4 th week post carotid artery ligation.
Static adhesion of mice bone marrow cells to CX 3 CL1 coated plate 48-well plates were coated for 1 hour with a 1:200 dilution of a mouse antipolyHis tag antibody (HIS-1, Sigma Aldrich, Arklow, Ireland) in bicarbonate buffer, pH 9.6 with 0.1% BSA. Subsequently, selected wells were coated with 100 nM rmCX 3 CL1 (R&D System, Abingdon, UK) for 1 hr. Since recombinant CX3CL1 is expressed with a C-terminal 6-histidine tag to facilitate purification using nickel agarose, an anti-His tag antibody was coated onto the plate to assist CX3CL1 capture and orientation [25] . CX 3 CR1 cells isolated from bone marrow of CX 3 CR1 gfp/+ mice were pre-treated with or without CX 3 CR1 peptide antagonist (F1; 2.5 and 5 mM) and were allowed to adhere to wells and then washed with PBS (36) . Attached cells were then labelled with Hoechst dye and counted using UV microscopy. The number of cells per field (106 objective) was expressed as mean 6 SEM.
Mouse model of experimental plaque neovascularization
A murine plaque angiogenesis model previously employed by Sasaki et al [26] was used. Mice were anesthetised by intraperitoneal administration of ketamine (90 mg/kg) and xylazine (10 mg/kg) and the left carotid artery at its bifurcation was exposed by standard microsurgical procedure. An 8/0 suture was passed under the artery at its bifurcation and tied to create a complete occlusion of the artery following which the subcutaneous tissue and skin was closed with 6/0 sutures by standard surgical process. The sham mice underwent the surgical steps described above except for the ligation procedure. In treatment groups, two weeks post carotid ligation, the mice were treated with F1 (50 mg total dose) or saline i.p. every third day for 2 weeks. 24 hrs before tissue harvest, the mice were injected with fluorescent microspheres (2-2.5 mm diameter) via tail vein following which the mice were sacrificed by over dose of Sodium Pentobarbital (i.p.).The carotid artery was perfusion fixed using chilled PBS and 4% paraformaldehyde. Perfusion fixed carotid artery was dissected out and cleaned of surrounding fat and cellular debris before being embedded in OCT for cryosectioning.
In vivo Matrigel neovascularization assay 500 ml of Matrigel (GibcoH; Bio-Sciences, Dublin, Ireland) fortified with 1 ng/ml FGF was subcutaneously implanted into the right and left flank region of mice. At 4 weeks post Matrigel implantation the mice were injected i.v. with 100 ml of 0.05% Evans blue or saline via tail vein and the mice were sacrificed 4 hrs post injection by overdose of sodium pentobarbital (i.p.). In a separate set of studies 200 mg of Rhodamine Griffonia (Bandeiraea) Simplicifolia Lectin I(GSL I, BSL I) (Vector Labs, CA, USA) was administered to mice by tail vein 24 hrs before culling. The Evans blue content of Matrigel was determined by dissolving the Matrigel in formic acid and then by reading the absorbance at 620 nm. While the heme content was quantified by pyridine hemochrome spectrophotometric heme assay [27] . Separate Matrigel samples embedded in OCT were processed for immunofluorescence and immunocytochemistry.
Morphometric and immunofluorescence analysis of injured carotid artery and Matrigel 5 mM thick frozen sections from carotid artery were cut and stained with hematoxylin-Z and eosin and Trichrome stains (CellPath Ltd, Powys, UK). Tissue images were acquired using Nikon CCD camera attached to a Nikon microscope. Morphometric analysis was performed using NIH ImageJ software for data quantification.
For immunofluorescence detection of smooth muscle specific protein and GFP expression carotid artery/Matrigel sections were stained for calponin (rabbit anti calponin: 1:200; Epitomics, CA, USA), CX 3 CR1 (rabbit anti CX 3 CR1:1:50; ProSci Incorporated, CA, USA), F4/80 (Rat anti mouse F4/80: 1:100; eBioscience; Hatfield, UK), Laminin (mouse anti laminin: 1:500; Novus Biologicals, Cambridge, UK) and/or CD42b (rat anti CD42b: 1:200; emfret Analytics GmbH & co.KG, Eibelstadt, Germany). Goat anti-rabbit, anti-mouse or anti rat Alexa Fluor 546 or 488 (1:250 or 500; Abcam, Cambridge, UK) was used as secondary antibody and DAPI was used for nuclear staining. Rabbit, mouse or rat IgG (1:50 or 200; Abcam, Cambridge, UK) were used as isotype controls. No additional labelling was required for GFP. Several thin optical slices (thickness,0.7 mm) of high-resolution sequential confocal scans (Nikon eC1 plus, TE2000E) of carotid artery sections were acquired to identify single GFP + cells coexpressing smooth muscle marker and to avoid false positive images due to overlapping cells. The acquired images were coded and analysed by two observers blinded to the codes. The 3D reconstruction and analysis of the images was performed using IMARIS software (Bitplane Scientific Software, Zurich, Switzerland).
In vitro cell tubulation and tunneling assay in 3D matrix CX 3 CR1 positive cells were FACS sorted from whole bone marrow of CX 3 CR1
gfp/+ and CX 3 CR1 gfp/gfp mice and were sandwiched between DQ-red BSA (Invitrogen; Bio-Sciences, Dublin, Ireland) fortified Matrigel layers with CX 3 CL1 gradient in a 15 m-angiogenesis slide (Ibidi, Munich, Germany). CX 3 CL1 gradient was created by serially layering two layers of Matrigel consisting of 50 and 100 nM rmCX 3 CL1 respectively. The cells were imaged using high-resolution sequential confocal scans (Nikon eC1 plus, TE2000E) at 3 hrs and every day up to day 7 post seeding. A separate series of experiments were conducted in the absence and presence of Rho inhibitor (10 mM; Y27632; MERCK, Darmstadt, Germany). The acquired confocal images were 3D reconstructed and analysed using IMARIS software. gfp/+ and CX 3 CR1 gfp/gfp mice and were grown on 6 well plates at a seeding density of 7610 5 cells per well for 5 days with or without 100 nM rmCX 3 CL1 stimulation. In a parallel set of experiments the cell viability was assessed using FACS at day 5 using 7AAD staining. On day 5 the cells were removed by treating with 500 ml of 20 mM Ammonium Hydroxide +0.1% Triton X-100 incubated for 5 mins at 37uC. Following six washes with 1 ml TBS buffer (Tris HCL 50 mM, NaCl 100 mM, pH 8.0), ECM on the plate was removed in the presence of 1% SDS for Western blot analysis. Equal total protein was loaded for Western blot analysis and b-actin was probed as a loading control. The Laminin bands were quantified by digital densitometry normalised to density of respective b-actin bands.
Extracellular matrix detection
RhoA activation assay
Active RhoA expression during the in vitro cell tubulation and tunneling process was assessed using a commercial RhoA activation assay kit (Millipore Ireland BV, Cork, Ireland). Briefly, CX 3 CR1 positive cells FACS sorted from whole bone marrow of CX 3 CR1 gfp/+ mice were plated in 6 well plates at a density of 7610 5 cells per well and were stimulated with 100 nM rm CX 3 CL1 for 30 mins. The cells were then lysed (Mg 2+ lysis/wash buffer) and the lysates were incubated with GST-tagged Rhotekin Rho binding domain for affinity precipitation of GTP-Rho. The bound GTP-Rho protein was pulled-down and resolved on 12% SDS-PAGE. The gel was transferred onto nitrocellulose membrane and detected by immunoblotting using 1:250 anti RhoA primary antibody (clone 55) and the appropriate peroxidaseconjugated secondary antibody and luminol based chemiluminescent HRP substrate (Millipore Ireland BV, Cork, Ireland). Whole cell lysate samples from all groups were also analysed by SDS-PAGE as total RhoA controls. The active-RhoA bands were quantified by digital densitometry normalised to density of respective total RhoA bands.
Statistics
All data are represented as mean 6 SEM and analysed by unpaired Student t-test or analysis of variance (ANOVA) using Graphpad Prism Version 4 (GraphPad Software, Inc., California, USA). Animal experiments with tissue section analysis were compared based on intra-experiment variation involving 3-4 mice/group that were not littermates.
Results
Bone marrow derived CX 3 CR1 positive cells contribute to formation of microvessels
In this study, myeloid phenotype of CX 3 CR1 expressing cells was established by FACS and tissue immunofluorescence ( Figure  S1 A, B.) indicating that the CX 3 CR1 transgenic models selected would be suitable for assessing structure function relationships between monocyte/macrophages and evolving neovascularization networks. We first assessed whether CX 3 CR1 positive cells contribute to microvasculature in a well-established in vivo model of Matrigel plug neovascularization. Following implantation of Matrigel (500 ml) in functional CX 3 CR1
gfp/+ and functionally incompetent CX 3 CR1
gfp/gfp mice microvascular association (perivascular) and integration(vascular) of CX 3 CR1 positive cells was assessed by immunofluorescence imaging, high resolution confocal microscopy with Z stacking and volume rendering. Functioning microvessels (MV) were identified by intravital staining of rhodamine conjugated lectin injected via tail vein. Functional CX 3 CR1 positive cells contribute to formation of plaque microvessels
Having established the perivascular and intravascular association of CX 3 CR1 cells with angiogenic MV in Matrigel, we investigated whether such an association exists with intimal MV using a recently described carotid artery ligation model of plaque neovascularization in mice [26] . We first established consistent development of carotid artery plaque that was rich in intimal microvessels ( To determine whether the effects of genetic functional deletion of CX 3 CR1 receptor on plaque neovascularization could be recapitulated by pharmacological inhibition of receptor activity, we treated wild type C57BL/J6 mice with a CX 3 CL1 analogue (F1 peptide) inhibitor of CX 3 CR1 receptor. The in vivo dose of F1 peptide was optimised based on the capacity of F1 peptide to inhibit binding of CX 3 CR1 positive cells to CX3CL1 coated plates in a static adhesion assay ( Figure S4 ) and on previously reported pharmacodynamic data [24] . 50 mg of F1 peptide was repeatedly administered every third day for 2 weeks by intraperitoneal injection starting from 2 weeks post carotid artery ligation (Figure 4 A). As observed in CX 3 CR1
gfp/gfp mice, F1 treated wild type mice exhibited significantly reduced staining for MV associated basement membrane laminin within the plaque (Figure 4 
Discussion
The major and new finding of this study is that functional competence of the monocyte/macrophage chemokine receptor CX 3 CR1 is essential for nascent microvessel formation, structural integrity and maturation in two models of neovascularization. Moreover, monocyte/macrophage tubulation, extracellular matrix tunneling and differentiation into smooth muscle-like cells within the microvasculature in vivo is driven in part by CX 3 CR1 interaction with its cognate ligand. CX 3 CR1-CX 3 CL1 association activates RhoA signalling, a central pathway in neovascularization/angiogenesis initiation and maintenance [29] . Abrogation of CX 3 CL1-CX 3 CR1 interaction reduces mural cell investment of nascent proangiogenic tubes in both models of neovascularization and reduces extracellular matrix protein production of laminin and collagen in a plaque neovascularization model ( Figure S5 ). Finally loss of CX 3 CR1 function or therapeutic targeting of CX 3 CR1 interaction using a mutant peptide CX 3 CL1-mimetic leads to development of smaller, poorly developed, leaky and remained in perivascular region (Scale bar: 10 mm). Microvessels formed in Matrigels isolated from CX 3 CR1 gfp/gfp mice were leaky, which was evident by increased heme content (D & E), Evan's blue dye leak (F & G), and extravasated platelets (CD42b; Red) (H & I) in the matrix compared to Matrigels implanted in CX 3 CR1 +/gfp mice. Data is represented as mean 6 SEM of 8 Matrigels/group and 10 Matrigel sections/mice (n = 4 independently performed experiments); * denotes p,0.05. doi:10.1371/journal.pone.0057230.g001 Figure 2 . CX 3 CR1 positive cells contribute to formation of experimental plaque angiogenesis. Plaque angiogenesis was created by ligation of carotid artery at its bifurcation for 4 weeks in CX 3 CR1
+/gfp and CX 3 CR1 gfp/gfp mice. Perfusion fixed carotid arteries were isolated and OCT embedded. 5 mm cross sections were stained with smooth muscle marker (Calponin; Red) and confocal images were acquired. A, Representative bright field cross section image of carotid artery from CX 3 CR1
+/gfp mice stained with DAPI (Nucleus; Blue). Red blood cells (RBCs) (arrow heads) were observed in the microvessels indicating these microvessels were functional. B, Mice competent for CX 3 CR1 function had a higher proportion of MV containing RBCs C, Representative cross section image of carotid artery from CX 3 CR1
+/gfp and CX 3 CR1 gfp/gfp mice were stained with calponin (Red) and DAPI (nucleus; blue). CX 3 CR1 positive cells (GFP positive; Green) integrated into microvascular wall and were also present in perivascular region and co-expressed smooth muscle marker (Calponin; Red) (Scale bar: 10 mm). In the CX 3 CR1 functionally deficient (CX 3 CR1 gfp/gfp ) mice the number of vascular and perivascular cells (GFP positive; Green) (D) and co-expressing smooth muscle marker (E) were significantly reduced. Data is expressed as mean 6 SEM of 20 carotid artery cross sections/mice (n = 4 independently performed experiments). F, Microvessels in the plaque stained with CX 3 CR1 (Green) and DAPI (nucleus; blue) were 3D reconstructed using IMARIS software to depict signet ring structures and their tubular architecture. G, The number of signet-ring cells was significantly reduced in CX 3 Monocyte/macrophage regulation of neovascularization has been extensively investigated over the past decade and is known to involve both paracrine [31] and cell-cell interactions [32] . Moreover, pioneering studies by Moldovan and colleagues have demonstrated that monocyte-macrophages drill tunnels in extracellular matrix to facilitate initial ingrowth of new capillaries [4, 12, 13, 33] . Thus monocyte/macrophages can provide paracrine and scaffold support for initiation, expansion and maturation of microvascular networks. However little is known about which myeloid cell population or surface receptors are implicated in signalling and morphogenesis and maturation of neovascular networks.
In both models of neovascularization used in our study it is likely that CX 3 CL1 [28] as well as other chemokines [12, 13] initiated recruitment of CX 3 CR1 positive cells into areas of microvessel growth. Although CX 3 CR1 is the only known receptor for CX 3 CL1, a recent study reported CX 3 CL1 induced angiogenesis, cell tubulation and signalling being partially insensitive to pertussis toxin pre-treatment [21] . Interestingly we also observed CX 3 CL1 induced tubulation events in CX 3 CR1 deficient cells ( Figure 5B ) and signet ring like structures in carotid artery plaques from CX 3 CR1 deficient mice ( Figure 2C ), thus indicating possibility of CX 3 CR1 independent effects of CX 3 CL1. Nevertheless, we show here that for the most part competence of CX 3 CR1 cells to interact with CX 3 CL1 ligand likely determines the spectrum of cell differentiation events that subsequently occurs post chemokine-receptor interaction [17, 34, 35] . Previously, we have identified smooth muscle cell differentiation as an important effect of CX 3 CL1-CX 3 CR1 interaction post arterial wire injury [17] . In the current study we extend these findings to a spectrum of additional downstream effects starting with augmented RhoA signalling, a pathway central to neovascularization/angiogenesis initiation with key functions regulating actin cytoskeleton, cell polarity and vacuolation [29] . We show in vitro that CX 3 CR1-CX 3 CL1 interaction increases RhoA activation and that monocyte/macrophage vacuolation downstream of CX 3 CL1 activation is completely abrogated by a Rho antagonist-Y27632 suggesting this cytoskeletal effect of CX 3 CR1 receptor activation may be driven at least in part by a Rho dependent mechanism. Since Rho activation initiates multiple other downstream pathways including smooth muscle cell differentiation [36] and extracellular matrix production [37, 38, 39, 40, 41] it is not surprising that CX 3 CR1-CX 3 CL1 interaction also augments laminin production and extracellular matrix tunnelling and migration activity of these activated monocyte/macrophages.
Consistent with these in vitro findings we show that CX 3 CR1 positive cells also exhibit a distinct tubulation phenotype change in vivo in the form of signet ring cell (a single DAPI nucleus and GFP positive ring cytoplasm) formation ( Figure 2F ). Monocyte/ macrophage tubulation (signet-ring formation) was impaired in CX 3 CR1 deficient mice and together with previous work by Moldovan and colleagues [4, 13] it is conceivable that impairment of Rho dependent cytoskeletal changes may have impaired initiation and maturation of nascent microvessels in these animals. Although no RBCs were observed within these tubular single cell structures we could readily demonstrate RBCs within two other MV-associated CX 3 CR1 phenotypes namely perivascular and mural (vascular) cell types. Consistent with our previous evidence for CX 3 CR1 differentiation into SM-like cells we show that almost all mural CX 3 CR1 positive cells within MVs co-express smooth muscle markers [16, 17] . More importantly functional deficiency of CX 3 CR1 markedly reduced in vivo mural and perivascular association of CX 3 CR1 cells within plaque MVs and mural association within Matrigel MV. Functional deficiency of CX 3 CR1 also reduced MV associated extracellular matrix production with more than 70% reduction in MV-associated laminin and collagen staining in CX 3 CR1 deficient mice. The functional consequences of aberrant CX 3 CR1 phenotype included increased microvascular leakage of blood, platelets, and intravascularly administered solutes (Evans Blue dye). It is tempting to speculate whether failure of CX 3 CR1 deficient cells to tubulate, or initiate differentiation into mural smooth muscle-like cells or impairment of extracellular matrix production may be significant contributors to increased microvessel porosity to blood and solutes in vivo thus providing a mechanism underlying the leaky MV phenotype. It is also conceivable that reduced mural CX 3 CR1 positive cells may have effects on microvascular endothelial permeability [42] .
Our current findings contribute to emerging literature on the direct involvement of monocyte/macrophages to smooth muscle cell differentiation [35, 43, 44] and extra cellular matrix [43, 44, 45] production within the vessel wall and supports the hypothesis of CX 3 CR1 positive cells contributing to formation of stable MV within neovascular networks and within experimental plaque. The monocyte/macrophage contribution to stable MV may thus occur via a number of mechanisms including inter alia differentiation of myeloid cells into smooth muscle cells, intra-mural and perivascular cell integration, synthesis of basement membrane, and paracrine secretion of other extracellular matrix support factors by these cells. Additionally CX 3 CR1 positive cells contribute to formation of stable MV in a plaque-independent setting, as indicated by our in vivo Matrigel induced neovascularization data.
While the implantation of a subcutaneous Matrigel plug is accepted as an excellent model of in vivo neovascularization, controversy remains on the appropriateness of current plaque neovascularization models used in mice. This limitation was recently addressed by Sasaki et al [46] wherein ligation of common carotid artery in a murine model was shown to develop a lesion with reproducible intimal neovascularization [46] . Thus we adapted this model for our current CX 3 CR1 studies and provide clear evidence of functional MV formation in this model using high resolution 3D confocal imaging.
Given that microvessel integrity and function is increasingly investigated as a potential contributor to plaque growth and stability we examined whether therapeutic targeting of CX 3 CR1 would alter MV structure and function. Remarkably, treatment of wild type mice with a CX 3 CL1 peptide-mimetic (F1) that specifically antagonized CX 3 CR1 recapitulated the leaky microvessel phenotype seen in CX 3 CR1 deficient mice. These F1 treated animals also exhibited marked reduction in basement membrane-laminin MV coverage, increased platelet extravasation and excess leakage of intravascularly administered microspheres compared to control treated animals. These data confirm that CX 3 CR1 deficiency or specific small molecule targeting of CX 3 CR1 reduces neovascularization ( Figure S7 , S8) and alters microvascular structure in vivo. Our data also illustrate that by presence of intravenously administered (tail vein) 2-2.5 mm diameter microspheres (red spheres) in the neointimal lesion (F & G therapeutic interference in microvascular structure-function may potentially be a double edged sword with unintended consequences such as microvascular leakage. This is especially relevant given the recent increase in cardiovascular events observed in patients receiving anti-angiogenic therapy for cancer (VEGF inhibitorAvastin) [47] . Thus, although enthusiasm is growing for targeting plaque neovascularization in humans our data suggests caution is required as complex interactions between evolving microvasculature and plaque growth and stability may not be easily amenable to single molecule therapeutic approaches. +/gfp and CX 3 CR1 gfp/gfp mice were stained with asmooth muscle actin (a-SMA; Red) and DAPI (nucleus; blue). CX 3 CR1 positive cells (GFP positive; Green) integrated into microvascular wall and were also present in perivascular region and co-expressed smooth muscle marker (a-SMA; Red) (Scale bar: 10 mm). E, In the CX 3 CR1 functionally deficient (CX 3 CR1 gfp/gfp ) mice the number microvascular CX 3 CR1 positive cells coexpressing smooth muscle marker were significantly reduced. Data is expressed as mean 6 SEM of 20 carotid artery cross sections/mice (n = 4 independently performed experiments). * denotes p,0.01. 
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